New Phase 2 REC-4881 data show durable polyp burden reductions in FAP
RXRX•Recursion Pharmaceuticals said Phase 2 REC-4881 data showed a 47% median polyp burden reduction, with 85% of evaluable patients below baseline after 12 weeks off treatment. The company plans to initiate a registrational trial in the second half of 2027.
1. Phase 2 results
The Phase 2 trial showed a 47% median polyp burden reduction, and 85% of evaluable patients remained below baseline after 12 weeks off treatment. Nearly 50% of upper-GI patients and 33% of lower-GI patients achieved at least a 65% reduction; the company reported no new safety signals.
2. Next trial planned
Recursion said it plans to initiate a registrational trial for REC-4881 in the second half of 2027.
